CL2015002253A1 - Composiciones farmacéuticas para el tratamiento de la helicobacter pylori. - Google Patents

Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.

Info

Publication number
CL2015002253A1
CL2015002253A1 CL2015002253A CL2015002253A CL2015002253A1 CL 2015002253 A1 CL2015002253 A1 CL 2015002253A1 CL 2015002253 A CL2015002253 A CL 2015002253A CL 2015002253 A CL2015002253 A CL 2015002253A CL 2015002253 A1 CL2015002253 A1 CL 2015002253A1
Authority
CL
Chile
Prior art keywords
helicobacter pylori
treatment
pharmaceutical compositions
composition
release dosage
Prior art date
Application number
CL2015002253A
Other languages
English (en)
Inventor
Reza Fathi
Gilead Raday
Guy Goldberg
Patrick Gosselin
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of CL2015002253A1 publication Critical patent/CL2015002253A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE 1) UNA PRIMERA COMPOSICION DE DOSIFICACION DE LIBERACION INMEDIATA QUE COMPRENDE AL MENOS DOS ANTIBIOTICOS, 2) UNA SEGUNDA COMPOSICION DE DOSIFICACION DE LIBERACION RETARDADA QUE COMPRENDE UN INHIBIDOR DE LA BOMBA DE PROTONES Y UN REVESTIMIENTO, Y 3) UNA CAPA EXTERIOR QUE ENCAPSULA LA PRIMERA Y LA SEGUNDA COMPOSICIONES DE DOSIFICACIÓN, UTIL PARA TRATAR HELICOBACTER PYLORI.
CL2015002253A 2013-02-13 2015-08-12 Composiciones farmacéuticas para el tratamiento de la helicobacter pylori. CL2015002253A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764401P 2013-02-13 2013-02-13
US201361764385P 2013-02-13 2013-02-13

Publications (1)

Publication Number Publication Date
CL2015002253A1 true CL2015002253A1 (es) 2016-07-29

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002253A CL2015002253A1 (es) 2013-02-13 2015-08-12 Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.

Country Status (26)

Country Link
US (7) US9050263B2 (es)
EP (1) EP2956149B1 (es)
JP (1) JP6494529B2 (es)
KR (1) KR102062357B1 (es)
CN (2) CN105163743A (es)
AU (1) AU2014216373B2 (es)
BR (1) BR112015019264B1 (es)
CA (1) CA2900763C (es)
CL (1) CL2015002253A1 (es)
CY (1) CY1122113T1 (es)
DK (1) DK2956149T3 (es)
ES (1) ES2744406T3 (es)
HK (1) HK1217645A1 (es)
HR (1) HRP20191559T1 (es)
HU (1) HUE052411T2 (es)
IL (1) IL240387B (es)
MX (1) MX368536B (es)
NZ (1) NZ711754A (es)
PH (1) PH12015501783B1 (es)
PL (1) PL2956149T3 (es)
PT (1) PT2956149T (es)
RU (1) RU2671400C2 (es)
SG (1) SG11201506318QA (es)
SI (1) SI2956149T1 (es)
UA (1) UA120249C2 (es)
WO (1) WO2014127025A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2956149T3 (da) 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
JP2018149269A (ja) * 2017-01-18 2018-09-27 マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル 消化管感染症に対する管腔内治療システム
EP3551186A4 (en) * 2017-10-15 2020-08-19 The Center for Digestive Diseases COMPOSITIONS AND METHODS FOR THE TREATMENT, IMPROVEMENT AND PREVENTION OF H. PYLORI INFECTIONS
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
KR20230150745A (ko) * 2022-04-22 2023-10-31 한국생명공학연구원 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
EP0941101A1 (en) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
CN101755205B (zh) 2007-07-20 2012-01-11 兴和株式会社 铅浓度测定用试剂以及铅浓度测定方法
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
DK2956149T3 (da) * 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori

Also Published As

Publication number Publication date
SI2956149T1 (sl) 2019-11-29
PH12015501783A1 (en) 2015-12-07
BR112015019264B1 (pt) 2021-08-24
DK2956149T3 (da) 2019-09-09
PH12015501783B1 (en) 2015-12-07
CA2900763C (en) 2021-04-06
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
EP2956149A1 (en) 2015-12-23
IL240387B (en) 2020-02-27
US11931463B2 (en) 2024-03-19
US9050263B2 (en) 2015-06-09
WO2014127025A1 (en) 2014-08-21
US10898439B2 (en) 2021-01-26
KR20150118176A (ko) 2015-10-21
CY1122113T1 (el) 2020-11-25
US9603806B2 (en) 2017-03-28
US20170189341A1 (en) 2017-07-06
BR112015019264A8 (pt) 2019-11-12
MX368536B (es) 2019-10-07
US20160235681A1 (en) 2016-08-18
IL240387A0 (en) 2015-09-24
KR102062357B1 (ko) 2020-01-03
US20150044283A1 (en) 2015-02-12
RU2015138708A (ru) 2017-03-17
EP2956149B1 (en) 2019-06-19
US9498445B2 (en) 2016-11-22
US20190336451A1 (en) 2019-11-07
SG11201506318QA (en) 2015-09-29
BR112015019264A2 (pt) 2017-07-18
CN109893516A (zh) 2019-06-18
JP6494529B2 (ja) 2019-04-03
US10238606B2 (en) 2019-03-26
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
CN105163743A (zh) 2015-12-16
HUE052411T2 (hu) 2021-04-28
US20220062188A1 (en) 2022-03-03
NZ711754A (en) 2020-05-29
PL2956149T3 (pl) 2020-03-31
US20190175512A1 (en) 2019-06-13
CA2900763A1 (en) 2014-08-21
MX2015010490A (es) 2015-10-30
EP2956149A4 (en) 2016-10-12
JP2016508516A (ja) 2016-03-22
US20140227353A1 (en) 2014-08-14
AU2014216373A1 (en) 2015-08-27
ES2744406T3 (es) 2020-02-25
HRP20191559T1 (hr) 2019-11-29
AU2014216373B2 (en) 2017-12-21
HK1217645A1 (zh) 2017-01-20

Similar Documents

Publication Publication Date Title
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112019011702A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR098168A1 (es) Formulación estable de insulina glulisina
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CR20150275A (es) Composición de difenidol de liberación prolongada
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
UY35690A (es) Composiciones farmacéuticas de ranolazina y dronedarona
EA201890477A1 (ru) Инкапсулированная композиция финголимода
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
GB2543709A (en) Pharmaceutical agent